Methyl 2-Bromo-5-Methyl-1,3-Thiazole-4-Carboxylate
|
HS Code |
230383 |
| Name | Methyl 2-Bromo-5-Methyl-1,3-Thiazole-4-Carboxylate |
| Molecular Formula | C6H6BrNO2S |
| Molecular Weight | 236.09 |
| Appearance | Solid (usually) |
| Solubility In Water | Low (organic compound, likely sparingly soluble) |
| Solubility In Organic Solvents | Soluble in common organic solvents like dichloromethane, chloroform |
| Purity | Can vary depending on source, typically high for pure products |
| Chemical Category | Thiazole - carboxylate derivative |
| Color | Colorless to pale yellow (common for such compounds) |
As an accredited Methyl 2-Bromo-5-Methyl-1,3-Thiazole-4-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of Methyl 2 - Bromo - 5 - Methyl - 1,3 - Thiazole - 4 - Carboxylate in sealed chemical - grade packaging. |
| Shipping | Methyl 2 - Bromo - 5 - Methyl - 1,3 - Thiazole - 4 - Carboxylate is shipped in accordance with chemical safety regulations. It's carefully packaged to prevent breakage and leakage, and transported by approved carriers ensuring secure transit. |
| Storage | Methyl 2 - Bromo - 5 - Methyl - 1,3 - Thiazole - 4 - Carboxylate should be stored in a cool, dry, well - ventilated area. Keep it away from heat sources, flames, and oxidizing agents. Store in a tightly sealed container to prevent moisture absorption and potential reactions. Avoid storage near incompatible substances to ensure its stability and safety. |
Without preamble, a technical paragraph introduces the first scenario—C–C bond formation via palladium-catalyzed cross-coupling, which accounts for the largest single usage of commercial methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate in early-stage pharmaceutical development.The compound functions as a hetaryl bromide electrophile in Suzuki-Miyaura reactions where the thiazole 4-carboxylate ester remains intact to preserve downstream hydrolytic lability for late-stage carboxylic acid unveiling. A standardised protocol validated on 500-litre glass-lined reactors at 1.2–1.5 kmol scale couples the bromothiazole with (4-fluorophenyl)boronic acid at 1.08 equiv boronic acid stoichiometry to compensate for protodeboronation losses observed above 65°C. The catalyst system employs Pd(dppf)Cl₂·CH₂Cl₂ at 0.5 mol% Pd loading, with K₃PO₄ (2.5 equiv) as base in degassed toluene/water (4:1 v/v) under a nitrogen blanket. Initiation at 50°C with a 12°C exotherm cap prevents premature catalyst reduction that triggers inactive palladium black precipitation. After 4.5 h at 62°C, IPC monitoring via HPLC (C18 column, 254 nm) shows residual bromothiazole below 0.3 area%. Workup involves filtration through a 0.5 µm inline bag filter, phase separation, and azeotropic distillation of toluene replaced with isopropanol for direct crystallization. The bis-aryl thiazole ester intermediate routinely achieves 97.4–98.2% purity (HPLC area) before further derivatization. This substrate topology appears in sartan-class antihypertensive discovery programs and in MCH-1 receptor antagonist clinical candidates. Residual palladium content is controlled to < 10 ppm per ICH Q3D Elemental Impurities Guideline by treatment with Si-Thiol scavenger resin (capacity 1.3 mmol/g) at 60°C for 2 h in ethanol. The European Pharmacopoeia (Ph. Eur. 10.0, monograph 2.5.37) heavy metals test is routinely met on pilot batches.Cephalosporin C-7 Substituent EngineeringThird-generation cephalosporins with extended Gram-negative coverage frequently incorporate a substituted thiazole ring at the C-7 side-chain position to modulate penicillin-binding protein affinity. Methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate is converted to the corresponding 2-amino derivative via copper-catalyzed amination with ammonia gas in ethylene glycol at 110°C, forming the free amine used directly in subsequent acylation. On a 200-litre Hastelloy autoclave rated to 6 bar, 28 kg of bromothiazole is dissolved in 220 L anhydrous ethylene glycol with 0.18 eq Cu₂O and 0.3 eq N,N’-dimethylethylenediamine ligand. Anhydrous ammonia is sparged subsurface at 1.2–1.5 L/min while the jacket temperature is ramped to 115°C over 50 min. The pressure is maintained at 4.5 bar for 18 h. Post-reaction, the mixture is cooled to 40°C and ammonia is stripped under 200 mbar vacuum into a water scrubber. The product 2-amino-5-methylthiazole-4-carboxylate ester is extracted into ethyl acetate and crystallized as the hydrochloride salt by adding 1.05 eq HCl in dioxane, isolated after centrifugation and vacuum drying at 45°C for 10 h. The salt is then coupled with a 7-ACA (7-aminocephalosporanic acid) activated ester using pivaloyl chloride/mixed anhydride activation in dichloromethane at −15°C. The chemoselectivity depends on maintaining a strictly anhydrous environment; residual water above 0.05% in DCM leads to formation of the δ-lactone byproduct from β-lactam ring opening, as measured by Karl Fischer titration before reaction. The final cephalosporin undergoes ICH Q3A forced degradation studies, where the thiazole C-4 methyl ester proves stable under acidic hydrolysis (pH 1.2, 37°C, 24 h) but hydrolyzes under alkaline stress (pH 10.0, 40°C, 6 h) to the carboxylic acid, a degradation pathway tracked by LC-MS.When Bromine Serves as the Leaving Group in Integrase Inhibitor AssemblyHIV-1 integrase strand transfer inhibitors (INSTIs) with a naphthyridine or quinoline carboxamide core frequently present a functionalized thiazole amide motif derived from this brominated precursor. The synthetic sequence employed on production-scale vessels involves initial saponification of methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate to the potassium salt followed by amide coupling. In a 500-litre glass-lined reactor, 45 kg of ester is saponified using 1.3 eq KOH in methanol/water (3:1) at 25–30°C, maintaining the temperature below 32°C to avoid decarboxylation that becomes kinetically measurable above 40°C (Arrhenius extrapolation from DSC data shows onset at 42°C). The potassium salt precipitates upon acetone addition, is collected on a centrifuge, and dried to < 0.5% moisture. The free acid is generated in situ by treating the potassium salt with 1.0 eq methanesulfonic acid in THF at 0°C, then converted to a mixed anhydride with isobutyl chloroformate and N-methylmorpholine. Reaction with the appropriate aminonaphthyridine hydrochloride at −5°C to 0°C yields the 2-bromothiazole carboxamide intermediate. This amide is then subjected to a secondary Buchwald-Hartwig amination with 2,4-difluorobenzylamine to replace the bromine atom, furnishing the final INSTI scaffold. Control of the amination step is paramount: catalyst poisons from residual metals in the naphthyridine segment suppress Pd₂(dba)₃/XPhos catalyst activity, requiring pre-treatment with activated carbon (Norit SX Plus) and filtration through a 0.2 µm cartridge filter. The finished API must comply with USP <232>/<233> elemental impurities limits, with special attention to Pd (<10 µg/g) and Cu (<250 µg/g). Stability-indicating methods per ICH Q2(R1) separate the 4-desmethyl thiazole degradant observed at high humidity storage (40°C/75% RH) due to ester hydrolysis, a critical quality attribute listed in the Active Substance Master File.In the manufacture of agricultural thiazole fungicides, specifically those targeting oomycete pathogens in solanaceous crops, the methyl ester function serves a dual purpose: it is a temporary protection group during heterocycle elaboration and a directing group for regioselective electrophilic substitution. A representative production campaign uses methyl 2-bromo-5-methyl-1,3-thiazole-4-carboxylate as starting material transformed through halogen exchange and 2-position acylation. The bromine atom is first displaced by potassium fluoride in sulfolane with tetraphenylphosphonium bromide as phase transfer catalyst at 180°C, yielding 2-fluoro-5-methylthiazole-4-carboxylate ester in 82% isolated yield after vacuum distillation (bp 128–132°C at 12 mmHg). This fluorine intermediate undergoes directed ortho-lithiation at the 5-methyl group with LDA at −78°C in THF, quenched with dimethylformamide to install a formyl group at the 5-position. The resulting aldehyde is condensed with thiosemicarbazide, cyclized with acetic anhydride to the thiadiazole ring, and finally converted to the propargyl carbamate that constitutes the commercial oomyceticide. The entire sequence is executed under ISO 14001 environmental management; waste streams containing bromide salts are passed through an ion-exchange recovery column, and sulfolane is recycled by wiped-film evaporation at 140°C and 5 mbar. Residues of the bromothiazole ester in final agrochemical formulations are controlled to < 0.1% w/w as per FAO pesticide specifications, determined by GC-ECD after derivatization with N,O-bis(trimethylsilyl)trifluoroacetamide. Ecotoxicological data required under EU Regulation 1107/2009 for the starting material includes an acute Daphnia magna EC50 (48 h) of 4.2 mg/L and an algal growth inhibition EC50 (72 h) of 2.8 mg/L, classifying it as Aquatic Chronic 3 under CLP Regulation.What Makes 5-Methyl Substitution Critical in Polyether Ionophore Synthesis?Veterinary polyether ionophores used as coccidiostats in poultry production share a conserved thiazole carboxylic acid substructure that controls calcium ion binding affinity within the gut epithelium of Eimeria parasites. This application proceeds through hydrolysis of the methyl ester to the free acid, a step that must be carefully controlled to avoid decarboxylation of the thiazole-4-carboxylic acid, which occurs with measurable rate above 60°C in aqueous media. Hydrolysis is performed with 2.5 M NaOH in water/methanol (1:2) at 50°C for 5 h in a 300-litre stainless steel stirred reactor. After acidification with 6 N HCl to pH 2.0–2.5, the precipitated 2-bromo-5-methyl-1,3-thiazole-4-carboxylic acid is filtered, washed with ice-water, and dried in a fluid-bed dryer at 45°C to < 0.2% water. The acid is then activated as the acid chloride with thionyl chloride in toluene catalyzed by 0.2 mol% DMF at 80°C, generating a tractable intermediate that couples to the secondary alcohol of the ionophore backbone. The steric effect of the 5-methyl group is non-trivial: it decreases the electrophilicity of the adjacent carbonyl by ~0.3 pKa units compared to the 5-unsubstituted analogue, reducing premature aminolysis during the coupling and improving the yield of the desired ester-linked ionophore from 52% to 78% under identical conditions. Purification of the conjugated drug substance employs normal-phase flash chromatography on silica (particle size 40–63 µm) with heptane/ethyl acetate gradient elution, followed by recrystallization from acetonitrile. The finished product is analysed per the VICH GL11 impurity guideline; residual thiazole starting materials and related substances are quantified by HPLC-UV at 254 nm with a reporting threshold of 0.05%. GMP batch records for the bromothiazole acid intermediate must demonstrate compliance with EU 37/2010 for veterinary active substances, particularly absence of sulfonated byproducts arising from over-chlorination during acid chloride formation. When batch-to-batch variation in the thionyl chloride charge deviates by more than ±4%, the impurity profile shifts, requiring additional re-crystallization cycles noted in the Deviation Management System.Published data for vapor-phase applications of this specific brominated thiazole ester in OLED transport layers is limited to bench-scale demonstrations; however, its electron-deficient character and favourable sublimation temperature make it a candidate for n-type host matrix doping. The ester sublimates cleanly at 95–98°C under 10⁻⁶ Torr with < 0.5% residue measured by thermogravimetric analysis, a property evaluated in a Kurt J. Lesker dual-source vacuum deposition system at 5 × 10⁻⁷ Torr base pressure. When co-deposited with tris(8-hydroxyquinolinato)aluminium (Alq₃) at a 12% wt doping level, the thiazole ester acts as an electron-transporting co-host, shifting the recombination zone by approximately 8 nm toward the cathode according to electroluminescent layer thickness measurements. Device stability testing at constant current density 25 mA/cm² under nitrogen shows a luminance half-life of 350 hours, significantly below commercial benchmarks, indicating that this precursor requires further structural optimization—specifically replacement of the methyl ester with a more sterically hindered tert-butyl ester to reduce exciton-induced degradation. These preliminary findings have been documented in an internal technical bulletin and not yet subject to inter-laboratory round-robin validation, so all electron mobility and lifetime figures should be interpreted as single-laboratory results with no assigned ASTM consensus status. |
Competitive Methyl 2-Bromo-5-Methyl-1,3-Thiazole-4-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Methyl 2‑bromo‑5‑methyl‑1,3‑thiazole‑4‑carboxylate, CAS 1000288‑77‑6, is a heteroaromatic building block characterised by a bromine atom at the thiazole 2‑position and a methyl ester group at the 4‑position. The molecular formula is C6H6BrNO2S (Mr 236.09 g·mol−1). In the standardised synthesis routes operated by several fine‑chemical producers, the compound is obtained via regioselective bromination of the corresponding methyl 5‑methyl‑1,3‑thiazole‑4‑carboxylate with N‑bromosuccinimide in acetonitrile or DMF, followed by aqueous work‑up and recrystallisation. Commercial product is typically supplied as a white to off‑white crystalline powder; the crystalline habit, confirmed by XRPD on representative lots, is primarily orthorhombic with a melting endotherm onset at 68–71 °C as determined by differential scanning calorimetry at a scan rate of 10 K·min−1. The bromine substitution pattern imparts reactivity suited for palladium‑catalysed cross‑coupling, while the methyl ester can be selectively hydrolysed to the free acid without affecting the bromine, a point of divergence from certain 2‑chloro analogues that demand harsher saponification conditions.
The bromination step, when performed in 200‑L glass‑lined reactors, exhibits a thermal profile that must be tightly controlled: the reaction mass self‑heats from 20 °C to 35 °C over 30–45 minutes after NBS addition, and an uncontrolled exotherm beyond 45 °C promotes di‑brominated by‑products as well as ring‑opening degradation pathways. In‑process HPLC analysis (Kromasil C18, 250 × 4.6 mm, 5 µm; mobile phase 45% acetonitrile/55% water + 0.1% TFA) detects the mono‑bromo ester at tR ≈ 8.7 min and the dibromo species at 10.2 min. Experienced campaign records from kilo‑lab and pilot‑plant batches show that the residual dibromo impurity, when kept below 0.5 area‑%, does not interfere with subsequent Suzuki coupling; however, concentrations exceeding 1.2 area‑% have been linked to diminished catalyst turnover numbers in Pd(OAc)2/SPhos systems. Isolated yields after crystallisation from heptane/ethyl acetate (9:1) average 68–74%, with batch‑to‑batch variation of ±3% attributable to the efficiency of the cold‑wash step that removes residual succinimide.
In certain production campaigns, a second polymorph – needle‑shaped monoclinic crystals – appears when the cooling rate during recrystallisation exceeds 2 K·min−1. This metastable form shows a melting point depression of 3–4 °C and an increased tendency to develop a brown discolouration on storage above 25 °C, even under nitrogen. Manufacturers that have transitioned to forced‑circulation crystallisers with controlled ramp profiles (e.g., Mettler‑Toledo Optimax equipped with PVM) maintain a consistent orthorhombic lot‑to‑lot morphology. The polymorphic identity is routinely verified by FT‑IR (KBr disc): the stable form shows a sharp carbonyl stretch at 1718 cm−1, while the metastable form produces a split band at 1712/1724 cm−1.
In medicinal chemistry programs pursuing biaryl‑linked kinase inhibitor scaffolds, Methyl 2‑bromo‑5‑methyl‑1,3‑thiazole‑4‑carboxylate is employed as the electrophilic partner in Suzuki‑Miyaura couplings with heteroaryl boronic esters. The electron‑withdrawing ester group activates the 2‑bromo substituent toward oxidative addition, but also moderates the tendency for protodebromination that can plague the corresponding 2‑iodo derivative when reactions are run above 60 °C. In a standardised screening protocol using Pd2(dba)3 (1 mol%) and XPhos (2.4 mol%) in degassed THF/water (3:1 v/v) with K3PO4 at 55 °C, the bromo ester provides complete conversion within 2 hours, while the chloro analogue requires 12 hours and elevated temperature (80 °C) to reach comparable conversion. The methyl ester group remains intact under these conditions, enabling direct isolation of the coupled product without ester hydrolysis; when the free acid is required, a final‑stage saponification with LiOH in THF/water at 0 °C cleanly delivers the carboxylic acid without ring‑opening or bromide displacement.
The methyl ester is preferred in applications where intermediate polarity and relatively low steric bulk are advantageous. In normal‑phase flash chromatography (CombiFlash systems, 40–63 µm silica), the methyl ester elutes earlier than the ethyl analogue, an important practical difference when the subsequent coupling product mixture contains unreacted boronic acid residues. In continuous‑flow hydrogenation setups (H‑Cube Mini, 10% Pd/C cartridge), the methyl ester exhibits a residence‑time‑limited reduction profile that allows selective nitro‑group reduction on appended aryl rings without ester cleavage; the tert‑butyl ester, in contrast, undergoes partial thermolytic deprotection at the 60–80 °C back‑pressure regulator temperature range commonly encountered in these flow reactors. Published data for this specific configuration is limited, yet process development groups have documented a superior selectivity window of 30‑minute cartridge life before breakthrough for the methyl ester, compared with 12‑minute for the tert‑butyl under identical conditions.
Two‑dimensional heterocyclic cores featuring a 2‑aryl‑5‑methylthiazole‑4‑carboxylate motif have been advanced to preclinical development in phosphodiesterase‑4 (PDE4) and colony‑stimulating factor‑1 receptor (CSF‑1R) programmes. The bromo intermediate’s value lies in its predictable reactivity profile, which readily accommodates a wide range of boronic acid coupling partners including electron‑poor pyridyl, pyrimidinyl, and pyrazolyl derivatives. In scale‑up campaigns for a Phase I CSF‑1R inhibitor, a kilo‑lab protocol using Pd(PPh3)4 (0.5 mol%) with Na2CO3 in dioxane/water at reflux delivered 86% isolated yield of the key biaryl intermediate after crystallisation, with palladium content below 10 ppm as measured by ICP‑OES following charcoal treatment. This contrast with 2‑chloro derivatives, which under the same catalyst loading gave 52% yield and required 2 equivalents of boronic acid to suppress homocoupling, is routinely cited in process chemistry reports as the driver for selecting the bromo building block.
| 2‑Halide variant | Reaction time (h) | Conversion (HPLC area‑%) | Isolated yield (%) | Protodehalogenation (%) |
|---|---|---|---|---|
| Methyl 2‑bromo‑5‑methyl‑1,3‑thiazole‑4‑carboxylate | 2 | 98 | 92 | <1 |
| Methyl 2‑chloro‑5‑methyl‑1,3‑thiazole‑4‑carboxylate | 12 | 83 | 74 | <1 |
| Methyl 2‑iodo‑5‑methyl‑1,3‑thiazole‑4‑carboxylate | 1.5 | 99 | 81 | 7 |
The following parameters are monitored and documented in a certificate of analysis per Ph.Eur. general chapters and JIS industrial standards. Retention samples held at 2–8 °C under argon in amber glass vials have demonstrated 99.5% purity retention after 24 months, with no appearance change or detectable insoluble fraction formation.
| Parameter | Specification | Analytical method |
|---|---|---|
| Appearance | White to off‑white crystalline powder | Visual inspection per Ph.Eur. 2.2.1 |
| Assay (HPLC, corrected for water) | ≥ 97.0% (anhydrous basis) | Ph.Eur. 2.2.29, external standard calibration |
| Water content (Karl Fischer) | ≤ 0.5% | Ph.Eur. 2.5.12 (Method I) |
| Melting point | 68–71 °C | Ph.Eur. 2.2.60, capillary method |
| Palladium (residual metals) | ≤ 5 ppm | ICP‑MS per USP <233> |
| Sulphated ash | ≤ 0.1% | Ph.Eur. 2.4.14 |
| Residual solvent (ethyl acetate) | ≤ 0.1% | GC‑HS per Ph.Eur. 2.4.24, System A |
The thermal stability envelope of the dry powder has been characterised by accelerating rate calorimetry (ARC): an onset of self‑sustaining decomposition is detected at 210 °C, with a pressure rise rate exceeding 100 bar·min−1 observed at 235 °C. Processing safety reviews conducted for 50‑kg campaigns in Hastelloy reactors establish a maximum jacket temperature of 120 °C during drying and a recommended nitrogen sweep rate of 0.5 vessel volumes per minute to keep the vapour phase below 25% of the lower explosive limit of any residual ethyl acetate. The presence of ≥ 0.8% moisture in the crude cake prior to drying has been correlated with darkening during final packing, attributed to acid‑catalysed hydrolysis of the ester that liberates methanol and generates the thermally less stable free acid. Therefore, the process instruction mandates a pre‑drying step at 35 °C under vacuum (10–15 mbar) until internal relative humidity falls below 20%, measured by a dew‑point transmitter in the vacuum line.
